Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 351 results found since Jan 2013.
Change of Serum Biomarkers to Post-Thrombolytic Symptomatic Intracranial Hemorrhage in Stroke
ConclusionsThis is the first study to identify changes in serum biomarkers in patients with sICH after IVT, and found that 6 neuroinflammatory and 3 neuroprotective biomarkers may be associated with brain injury following post-thrombolytic sICH.Clinical Trial Registrationhttps://www.clinicaltrials.gov, identifier: NCT02854592.
Source: Frontiers in Neurology - June 2, 2022 Category: Neurology Source Type: research
Anterograde Injection of Alteplase Salvages Deep Inferior Epigastric Perforator Flap in Reconstructive Breast Surgery
We report the case of a 43-year-old woman who underwent unilateral breast reconstruction with a DIEP flap at our department. Approximately 12 hours postoperatively, an arterial inflow problem was suspected and revision surgery was performed. Peripheral flap perfusion remained absent without an obvious cause and distal thrombosis was assumed to be present. Therefore, alteplase was gradually injected into the arterial pedicle in the anterograde direction just distal to the anastomosis while clamping the artery proximally. About 3 hours after selective flap thrombolysis, microcirculation of the flap was successfully restored ...
Source: Plastic and Reconstructive Surgery – Global Open - June 1, 2022 Category: Cosmetic Surgery Tags: Breast: Case Report Source Type: research
Effect of Alteplase Thrombolysis on Coagulation Function and Nerve Function of Patients with Ischemic Stroke
CONCLUSION: Alteplase thrombolysis showed benefits in mitigating the coagulation function and nerve function damage of patients with ischemic stroke, especially within 3 hours after the onset, with a high safety profile.PMID:35586691 | PMC:PMC9110162 | DOI:10.1155/2022/9440271
Source: Evidence-based Complementary and Alternative Medicine - May 19, 2022 Category: Complementary Medicine Authors: Hong-Ying Zhao Guo-Tao Yang Hui-Fang Zhang Wen-Hao Wang Source Type: research
ACT Tenecteplase Trial to Change Clinical Practice in Stroke? ACT Tenecteplase Trial to Change Clinical Practice in Stroke?
The largest trial so far conducted with the new bolus thrombolytic, tenecteplase, in acute ischemic stroke has shown noninferiority to alteplase with similar safety.Medscape Medical News
Source: Medscape Cardiology Headlines - May 5, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia following COVID-19 Vaccine: A Case Report with Systematic Review of the Literature
Conclusion: Our study points out that, in addition to cerebral venous thrombosis, adenoviral vector-based vaccines also appear to have a cerebral arterial thrombotic risk, and clinicians should be aware that ischemic stroke with LVO, although rare, could represent a clinical presentation of VITT.Cerebrovasc Dis
Source: Cerebrovascular Diseases - May 5, 2022 Category: Neurology Source Type: research
Tenecteplase in Mobile Stroke Unit Shows Encouraging Results Tenecteplase in Mobile Stroke Unit Shows Encouraging Results
Giving the bolus thrombolytic tenecteplase in a mobile stroke unit improved efficacy compared with the standard of care thrombolytic alteplase, without safety concerns, in the TASTE-A study.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - May 4, 2022 Category: Neurology Tags: Cardiology News Source Type: news
Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?
Expert Opin Investig Drugs. 2022 Apr 29. doi: 10.1080/13543784.2022.2072725. Online ahead of print.ABSTRACTINTRODUCTION: Stroke is a leading cause of disability and mortality and its burden expected to increase. The only approved drug for acute ischemic stroke is the intravenous thrombolytic alteplase. The risk of bleeding complications is one of the reasons for the undertreatment of eligible patients. Numerous drugs are currently being developed to improve safety-efficacy.AREAS COVERED: We reviewed literature from January 1st, 2000, to 15th January 2022 for the development and testing of novel drugs with the aim of target...
Source: Expert Opinion on Investigational Drugs - April 29, 2022 Category: Drugs & Pharmacology Authors: Maria Giulia Mosconi Maurizio Paciaroni Walter Ageno Source Type: research
An Optimal Animal Model of Ischemic Stroke Established by Digital Subtraction Angiography-Guided Autologous Thrombi in Cynomolgus Monkeys
ConclusionOur study may provide an optimal non-human primate model for an in-depth study of the pathogenesis and treatment of focal cerebral ischemia.
Source: Frontiers in Neurology - April 25, 2022 Category: Neurology Source Type: research
Advances in Acute Ischemic Stroke Therapy
Circ Res. 2022 Apr 15;130(8):1230-1251. doi: 10.1161/CIRCRESAHA.121.319948. Epub 2022 Apr 14.ABSTRACTThe treatment of acute ischemic stroke continues to advance. The mainstay of treatment remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later treatment with alteplase is beneficial in patients selected with advanced imaging techniques. Tenecteplase has been evaluated as an alternative thrombolytic drug and evidence suggests that it is as least as effective as alteplase and may lyse large vessel clots more effectively. Endovascular therapy with mechanical thrombectomy has now been shown to be...
Source: Circulation Research - April 14, 2022 Category: Cardiology Authors: Yunyun Xiong Ajay K Wakhloo Marc Fisher Source Type: research
Impact of poly-arginine peptides R18D and R18 on alteplase and tenecteplase thrombolysis in vitro, and neuroprotective stability to proteolysis
AbstractThe poly-arginine peptides R18D and R18 represent novel potential neuroprotective treatments for acute ischaemic stroke. Here we examined whether R18D and R18 had any significant effects on the thrombolytic activity of alteplase (tPA) and tenecteplase (TNK) on clots formed from whole blood in an in vitro thrombolysis plate assay. R18D and R18 were examined at concentrations of 0.25, 0.5, 1, 2, 4, 8 and 16  µM during the 1-h thrombolytic assay. We also included the well-characterised neuroprotective NA-1 peptide as a control. R18D, R18 and NA-1 all reduced tPA or TNK percentage clot lysis by 0–9.35%, 0–3.44% a...
Source: Journal of Thrombosis and Thrombolysis - March 19, 2022 Category: Hematology Source Type: research
